NEW YORK (GenomeWeb) – Transplant Genomics has raised $3.2 million in a private stock offering, according to a document filed with the US Securities and Exchange Commission.
The offering included new and existing investors, Transplant Genomics CEO Stanley Rose told GenomeWeb, but declined to identify them. Rose said the firm plans to use the proceeds to continue building its team to commercialize the TruGraf post-transplant diagnostic test and to fund clinical trials to establish the test's clinical utility as the firm looks to increase market adoption and pursue reimbursement for the test.
The firm's technology is for the detection of the early signs of graft injury and to differentiate between actionable causes and enable a personalized medicine approach to patient care.
A year ago, the firm raised $2.8 million in debt, options, warrants, and other rights to acquire other securities.